STATE-OF-THE-ART OF ZIDOVUDINE MONITORING

被引:22
作者
STRETCHER, BN [1 ]
机构
[1] UNIV CINCINNATI,COLL MED,DEPT PATHOL & LAB MED,CINCINNATI,OH 45221
关键词
AZIDOTHYMIDINE; AZT; THERAPEUTIC DRUG MONITORING; AIDS; HIV-INFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RADIOIMMUNOASSAY; FLUORESCENCE POLARIZATION IMMUNOASSAY;
D O I
10.1002/jcla.1860050112
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Zidovudine, the only drug approved by the FDA for the treatment of AIDS, has well-documented efficacy, but numerous toxic side effects. Despite considerable knowledge of the pharmacology of the drug, however, a therapeutic concentration range has not been established. This article reviews methodologies used for measurement of zidovudine in serum. Procedures for several methods are described and comparisons offered. In addition to methodologies, other issues of concern in establishing or maintaining a zidovudine monitoring service are also discussed, including the clinical relevance of routine zidovudine monitoring, method-related quality control, and laboratory safety. Methodologies currently being developed to measure the active intracellular metabolites of zidovudine are also described. These methods are believed to be the key to fully understanding the relationships between zidovudine pharmacology, toxicity, and efficacy.
引用
收藏
页码:60 / 68
页数:9
相关论文
共 51 条
  • [1] BIOCHEMICAL PHARMACOLOGY OF ZIDOVUDINE IN HUMAN T-LYMPHOBLASTOID CELLS (CEM)
    AVRAMIS, VI
    MARKSON, W
    JACKSON, RL
    GOMPERTS, E
    [J]. AIDS, 1989, 3 (07) : 417 - 422
  • [2] PHARMACOKINETICS OF ZIDOVUDINE ADMINISTERED INTRAVENOUSLY AND ORALLY IN CHILDREN WITH HUMAN IMMUNODEFICIENCY VIRUS-INFECTION
    BALIS, FM
    PIZZO, PA
    EDDY, J
    WILFERT, C
    MCKINNEY, R
    SCOTT, G
    MURPHY, RF
    JAROSINSKI, PF
    FALLOON, J
    POPLACK, DG
    [J]. JOURNAL OF PEDIATRICS, 1989, 114 (05) : 880 - 884
  • [3] THE INVITRO AND INVIVO ANTI-RETROVIRUS ACTIVITY, AND INTRACELLULAR METABOLISM OF 3'-AZIDO-2',3'-DIDEOXYTHYMIDINE AND 2',3'-DIDEOXYCYTIDINE ARE HIGHLY DEPENDENT ON THE CELL SPECIES
    BALZARINI, J
    PAUWELS, R
    BABA, M
    HERDEWIJN, P
    DECLERCQ, E
    BRODER, S
    JOHNS, DG
    [J]. BIOCHEMICAL PHARMACOLOGY, 1988, 37 (05) : 897 - 903
  • [4] BARONE GC, 1989 PITTSB C
  • [5] BAXTER R, 1989, 6TH AIDS CLIN TRIALS
  • [6] BOUCHER FD, 1989, 5TH INT C AIDS MONTR
  • [7] CHAVANET P, 1989, NEW ENGL J MED, V321, P1548
  • [8] CLINICAL PHARMACOKINETICS OF ZIDOVUDINE - AN OVERVIEW OF CURRENT DATA
    COLLINS, JM
    UNADKAT, JD
    [J]. CLINICAL PHARMACOKINETICS, 1989, 17 (01) : 1 - 9
  • [9] ALTERATION OF ZIDOVUDINE PHARMACOKINETICS BY PROBENECID IN PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX
    DEMIRANDA, P
    GOOD, SS
    YARCHOAN, R
    THOMAS, RV
    BLUM, MR
    MYERS, CE
    BRODER, S
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (05) : 494 - 500
  • [10] LACK OF ACTIVITY OF ZIDOVUDINE IN AIDS-ASSOCIATED KAPOSIS SARCOMA
    DEWIT, R
    REISS, P
    BAKKER, PJM
    LANGE, JMA
    DANNER, SA
    VEENHOF, KHN
    [J]. AIDS, 1989, 3 (12) : 847 - 850